EnteroMix: Promise and Peril in Russia’s Personalized Cancer Vaccine

By Peter A. McCullough, MD, MPH

The news was buzzing about a Russian cancer vaccine back in 2024-25. But the story has gone cold in 2026; I wondered why?


🔬 How It Works

EnteroMix is a Russian-developed therapeutic cancer vaccine combining two strategies. The first is an oncolytic viral cocktail — four replication-competent enteroviruses (CVA21, ECHO-7, EV-B75, and a poliovirus–rhinovirus chimera) that selectively infect and lyse tumor cells, releasing antigens and danger signals that “heat” the tumor microenvironment. The second is a personalized mRNA vaccine — synthesized from the patient’s own tumor RNA — that encodes patient-specific neoantigens, training T-cells to hunt cancer cells bearing those mutational signatures.

Subscribe now


Read more

 

IPAK-EDU is grateful to FOCAL POINTS (Courageous Discourse™) as this piece was originally published there and is included in this news feed with mutual agreement. Read More

Subscribe to SciPublHealth


Science-based knowledge, not narrative-dictated knowledge, is the goal of WSES, and we will work to make sure that only objective knowledge is used in the formation of medical standards of care and public health policies.

Comments


Join the conversation! We welcome your thoughts, feedback, and questions. Share your comments below.

Leave a Reply

Discover more from Science, Public Health Policy and the Law

Subscribe now to keep reading and get access to the full archive.

Continue reading